495 related articles for article (PubMed ID: 16791450)
21. Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sFlk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma.
Reinblatt M; Pin RH; Bowers WJ; Federoff HJ; Fong Y
Ann Surg Oncol; 2005 Dec; 12(12):1025-36. PubMed ID: 16244806
[TBL] [Abstract][Full Text] [Related]
22. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer.
Hotz HG; Hines OJ; Masood R; Hotz B; Foitzik T; Buhr HJ; Gill PS; Reber HA
Surgery; 2005 Feb; 137(2):192-9. PubMed ID: 15674201
[TBL] [Abstract][Full Text] [Related]
23. Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors.
Li M; Yang H; Chai H; Fisher WE; Wang X; Brunicardi FC; Yao Q; Chen C
Cancer; 2004 Nov; 101(10):2341-50. PubMed ID: 15476280
[TBL] [Abstract][Full Text] [Related]
24. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
25. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo.
Soh EY; Eigelberger MS; Kim KJ; Wong MG; Young DM; Clark OH; Duh QY
Surgery; 2000 Dec; 128(6):1059-65;discussion 1065-6. PubMed ID: 11114643
[TBL] [Abstract][Full Text] [Related]
26. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
[TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines.
Wey JS; Fan F; Gray MJ; Bauer TW; McCarty MF; Somcio R; Liu W; Evans DB; Wu Y; Hicklin DJ; Ellis LM
Cancer; 2005 Jul; 104(2):427-38. PubMed ID: 15952180
[TBL] [Abstract][Full Text] [Related]
28. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance.
Zhang L; Hannay JA; Liu J; Das P; Zhan M; Nguyen T; Hicklin DJ; Yu D; Pollock RE; Lev D
Cancer Res; 2006 Sep; 66(17):8770-8. PubMed ID: 16951193
[TBL] [Abstract][Full Text] [Related]
29. Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo.
Riedel F; Götte K; Li M; Hörmann K; Grandis JR
Int J Oncol; 2003 Sep; 23(3):577-83. PubMed ID: 12888890
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
[TBL] [Abstract][Full Text] [Related]
31. Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference.
Wang J; Shi YQ; Yi J; Ye S; Wang LM; Xu YP; He M; Kong XM
J Dig Dis; 2008 Nov; 9(4):228-37. PubMed ID: 18959596
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
33. Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization.
Yasui M; Yamamoto H; Ngan CY; Damdinsuren B; Sugita Y; Fukunaga H; Gu J; Maeda M; Takemasa I; Ikeda M; Fujio Y; Sekimoto M; Matsuura N; Weinstein IB; Monden M
Clin Cancer Res; 2006 Aug; 12(15):4720-9. PubMed ID: 16899623
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor immunoneutralization in combination with cisplatin reduces EAC tumor growth.
Ghosh S; Maity P
Int Immunopharmacol; 2006 Oct; 6(10):1550-9. PubMed ID: 16919827
[TBL] [Abstract][Full Text] [Related]
35. Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma.
Parikh AA; Liu WB; Fan F; Stoeltzing O; Reinmuth N; Bruns CJ; Bucana CD; Evans DB; Ellis LM
Cancer; 2003 Aug; 98(4):720-9. PubMed ID: 12910515
[TBL] [Abstract][Full Text] [Related]
36. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
Polverino A; Coxon A; Starnes C; Diaz Z; DeMelfi T; Wang L; Bready J; Estrada J; Cattley R; Kaufman S; Chen D; Gan Y; Kumar G; Meyer J; Neervannan S; Alva G; Talvenheimo J; Montestruque S; Tasker A; Patel V; Radinsky R; Kendall R
Cancer Res; 2006 Sep; 66(17):8715-21. PubMed ID: 16951187
[TBL] [Abstract][Full Text] [Related]
37. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression.
Itakura J; Ishiwata T; Friess H; Fujii H; Matsumoto Y; Büchler MW; Korc M
Clin Cancer Res; 1997 Aug; 3(8):1309-16. PubMed ID: 9815813
[TBL] [Abstract][Full Text] [Related]
38. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.
Borgström P; Gold DP; Hillan KJ; Ferrara N
Anticancer Res; 1999; 19(5B):4203-14. PubMed ID: 10628376
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101.
Murakami K; Sakukawa R; Sano M; Hashimoto A; Shibata J; Yamada Y; Saiki I
Clin Cancer Res; 1999 Sep; 5(9):2304-10. PubMed ID: 10499597
[TBL] [Abstract][Full Text] [Related]
40. A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth.
Ueda Y; Yamagishi T; Samata K; Ikeya H; Hirayama N; Okazaki T; Nishihara S; Arai K; Yamaguchi S; Shibuya M; Nakaike S; Tanaka M
Cancer Chemother Pharmacol; 2004 Jul; 54(1):16-24. PubMed ID: 15064856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
